We treated cell lines derived from TyrCREERT2B-RafV600Ezh2Y641F/+ melanoma with three EZH2 inhibitors: UNC1999 (ref. 36), GSK126 (ref. 37) and a previously unpublished SAM-competitive pyridinone inhibitor, JQEZ5....Ezh2 inhibitors demonstrate anti-neoplastic activity in Ezh2Y641F-mutant cancers